Terry J. Smith, MD

ATLANTA — In this video exclusive, Terry Smith, MD, discusses results of an analysis of clinical trial data on blood glucose effects associated with teprotumumab therapy for thyroid eye disease.

Teprotumumab was approved for the treatment of thyroid eye disease in January 2020. As real-world experience with teprotumumab increases, several clinical reports describing patient responses, safety and effectiveness are now appearing.